Longeveron Inc - Ordinary Shares - Class A Stock News

The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging No approved treatments for aging-related frailty, a syndrome affecting older individuals that impairs human Healthspan, and is characterized by weakness, low physical activity, slowed motor performance, exh...

Longeveron Inc. ( LGVN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Than Powell - Interim CEO & Director Nataliya Agafonova - Chief Medical Officer Devin Blass - CTO & Senior VP of Chemistry, Manufacturing, and Controls Lisa Locklear - CFO, Executive VP & Treasurer Joshua Hare - Co-Founder, Chief Science Officer & Executive Chairman Conference Call Participants Dere...

Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHS Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication ELPIS II top-line trial results are anticipated in the thi...

MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the 4th Annual ROTH Healthcare Opportunities Conference. Longeveron management will host one-on-one meetings with investors at the confe...

Exploring potential partnerships and strategic opportunities for the Company's stem cell therapy program in Alzheimer's disease Alzheimer's disease development program with positive data in successful Phase 1 and Phase 2a clinical trials Clear regulatory pathway following positive Type B meeting with U.S. FDA FDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) desig...

Than Powell, Chief Business Officer and head of business development, appointed Interim CEO Dr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of Directors Wa'el Hashad to step down as CEO and Board member National search to occur for permanent CEO MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerativ...

MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 in New York City.

Longeveron Inc. (NASDAQ:LGVN ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Devin Blass - CTO & Senior VP of Chemistry, Manufacturing, and Controls Joshua Michael Hare - Co-Founder, Chief Science Officer & Chairman Lisa A. Locklear - CFO, Executive VP & Treasurer Mohamed Wa'el Ahmed Hashad - CEO & Director Nataliya Agafonova - Chief Medical Officer Conference...